您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > PPOH
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
PPOH
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
PPOH图片
CAS NO:206052-01-9
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议
50mg电议

产品介绍
Cas No.206052-01-9
化学名2-(2-propynyloxy)-benzenehexanoic acid
Canonical SMILESC#CCOC1=CC=CC=C1CCCCCC(O)=O
分子式C15H18O3
分子量246.3
溶解度≤100mg/ml in ethanol;50mg/ml in DMSO;100mg/ml in dimethyl formamide
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

IC50: 9 μM for the formation of arachidonate 11,12 epoxides by CYP4A2 and CYP4A3 enzymes, respectively

PPOH is an inhibitor of CYP epoxidase activity on arachadonic acid.

Arachidonic acid can be converted by microsomal CYP450 enzymes to a variety of epoxides, ω-1 and ω-hydroxylated compounds through what is reported as the epoxidase pathway.

In vitro: A previous study found that the inhibition of the epoxygenase pathway with PPOH was able to enhance the microvascular response to increasing renal perfusion pressure. In the presence of 50 mM PPOH, afferent arteriolar diameter decreased by 29% when pressure was increased from 80-160 mmHg. In contrast, the selective CYT-P450 hydroxylase inhibitor, N-methylsulphonyl-12,12-dibromododec-11-enamide could attenuate the vascular response to increasing renal perfusion pressure [1]. In another study, it was shown that among the acetylenic compounds, both PPOH and N-methylsulfonyl-6-(2-propargyloxyphenyl)hexanamide were potent and selective inhibitors of microsomal epoxidation with IC50 values of 9 and 13 microM, respectively. Inhibition of microsomal activity by PPOH, but not DDMS, was time- and NADPH-dependent, which was a characteristic of a mechanism-based irreversible inhibitor [2].

In vivo: Up to now, there is no animal in vivo data reported.

Clinical trial: So far, no clinical study has been conducted.

References:
[1] Imig, J. D.,Falck, J.R., and Inscho, E.W. Contribution of cytochrome P450 epoxygenase and hydroxylase pathways to afferent arteriolar autoregulatory responsiveness. British Journal of Pharmacology 127, 1399-1405 (1999).
[2] Wang, M. H.,Brand-Schieber, E.,Zand, B.A., et al. Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: Characterization of selective inhibitors. Journal of Pharmacology and Experimental Therapeutics 284(3), 966-973 (1998).